The cover image is based on the Original Article Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study by Qinglei Gao et al., https://doi.org/10.1002/cac2.12233.

Pancreatic cancer is a highly malignant digestive system tumor with poor prognosis. Most pancreatic cancer patients are diagnosed at advanced stages or even metastasis due to its highly aggressive characteristics and the lack of early typical symptoms. Thus, the early diagnosis of pancreatic cancer is crucial for improving its prognosis

CRC represents the third most commonly diagnosed cancer and the second cause of cancer death;

Cell signaling pathways are dysregulated in CRC stem cells;

Cell signaling pathways are target to eradicate CRC stem cells.

An overview of the efficacy of PD-1/PD-L1 inhibitors in advanced NSCLC patients with EGFR mutation. We also focused on the mechanisms that affect the efficacy of ICIs in patients with EGFR mutation and further investigation worth to be done in future.

We discuss various methods for creation of organ-specific cancer organoids and summarize organ-specific advances and applications, synergistic technologies, and treatments as well as current limitations and future prospects for cancer organoids. Further advances will bring this novel 3D culture organoid technique closer to clinical practice in the future.

Our results identified that MAGE-C3 promotes tumor metastasis not only through the EMT but also by protecting tumors from immunosurveillance

Breast cancer patients had significantly higher serum SEMA4C levels than patients with benign breast tumor and normal controls. Serum SEMA4C is considered as a candidate diagnostic biomarker for the early detection and diagnosis of breast cancer.

An integrative score incorporating genetically predicted gene expression and DNA methylation and other genomic and non-genomic information advanced our understanding of using genomic information to stratify subjects for prostate cancer.